1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 25,200 | 25,600 | 09:55 | |
| 25,200 | 25,600 | 09:41 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.08. | Caris Life Sciences stock price target raised to $37 by BofA on strong ASP growth | 5 | Investing.com | ||
| 13.08. | Caris Life Sciences stock price target raised to $45 from $38 at BTIG | 3 | Investing.com | ||
| 13.08. | BTIG hebt Kursziel für Caris Life Sciences auf 45 $ an | 1 | Investing.com Deutsch | ||
| 13.08. | Caris Life Sciences stock price target raised to $40 from $33 at Evercore ISI | 2 | Investing.com | ||
| CARIS LIFE SCIENCES Aktie jetzt für 0€ handeln | |||||
| 13.08. | Evercore ISI hebt Kursziel für Caris Life Sciences auf 40 US-Dollar an | 2 | Investing.com Deutsch | ||
| 12.08. | Caris Life Sciences, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 12.08. | Caris Life Sciences: Aktie steigt nach deutlich angehobener Umsatzprognose | 2 | Investing.com Deutsch | ||
| 12.08. | Caris Life Sciences steigert Umsatz um 81 % und verbessert Margen im zweiten Quartal 2025 | 1 | Investing.com Deutsch | ||
| 12.08. | Caris Life Sciences, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 19.07. | Cathie Wood's Ark Invest Offloads Meta, Loads Up On Teradyne, Caris Life Sciences | 16 | Benzinga.com | ||
| 15.07. | Cathie Wood's ARK sells Roku, buys Caris Life Sciences stock | 22 | Investing.com | ||
| 14.07. | Wolfe Research startet Coverage für Caris Life Sciences mit "Outperform"-Rating | 3 | Investing.com Deutsch | ||
| 14.07. | Wolfe Research initiates Caris Life Sciences stock with Outperform rating | 3 | Investing.com | ||
| 14.07. | Evercore ISI initiates Caris Life Sciences stock with Outperform rating | 3 | Investing.com | ||
| 14.07. | Citi initiates Caris Life Sciences stock with Buy rating on profitability outlook | 2 | Investing.com | ||
| 14.07. | Caris Life Sciences stock initiated with Buy rating at TD Cowen | 1 | Investing.com | ||
| 14.07. | JPMorgan startet Coverage für Caris Life Sciences mit "Overweight"-Rating | 4 | Investing.com Deutsch | ||
| 14.07. | JPMorgan initiates Caris Life Sciences stock with Overweight rating | 2 | Investing.com | ||
| 14.07. | Guggenheim initiates coverage on Caris Life Sciences stock with Buy rating | 4 | Investing.com | ||
| 14.07. | Guggenheim stuft Caris Life Sciences mit "Buy" ein und sieht 20 % Kurspotenzial | 3 | Investing.com Deutsch |
1 2 3 Weiter >>
56 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 39,390 | -0,20 % | Kaum Impulse für die Qiagen NV-Aktie (37,58 €) | Wenig Kursbewegung zur Stunde bei dem Anteilsschein von Qiagen NV . Der jüngste Kurs betrug 37,58 Euro. Einen minimalen Wertanstieg von 0,17 Prozent zeigt die Kurstafel für der Anteilsschein von Qiagen... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 63,00 | +1,61 % | CRISPR Therapeutics AG: CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress | ||
| BIONXT SOLUTIONS | 0,502 | -2,71 % | BioNxt Solutions' Pharma-Revolution: Neue Wege der Wirkstoffverabreichung von Blockbustern | ||
| VIKING THERAPEUTICS | 23,510 | -1,18 % | Viking Therapeutics: Bald wieder im Rampenlicht? | Die Aktionäre von Viking Therapeutics mussten zuletzt einen herben Kursrückgang verkraften, während ein potenzieller Konkurrent für eine hohe Milliardenbewertung übernommen wurde. Dabei gilt Viking... ► Artikel lesen | |
| EDITAS MEDICINE | 3,317 | +0,06 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 19,400 | +1,73 % | S&P Dow Jones Indices: Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600 | NEW YORK, Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Inc. (NYSE: ELAN) will replace Sarepta Therapeutics Inc. (NASD: SRPT) in the S&P MidCap 400, and... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 47,400 | -0,04 % | BioMarin Pharmaceutical Inc.: BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism | New data from Phase 3 PEGASUS study demonstrates a 49.7% decrease in mean blood Phe levels in adolescents aged 12-17 treated with PALYNZIQ
BioMarin's planned submission... ► Artikel lesen | |
| EXELIXIS | 34,910 | -1,08 % | Morgan Stanley Maintains Overweight Rating For Exelixis, Inc. (EXEL), Price Target Raised To $50 | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,244 | +2,29 % | PacBio Enters Carrier Screening Market With PureTarget Expansion | ||
| ABIVAX | 70,70 | +0,14 % | EQS-News: ABIVAX: Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting | EQS-News: ABIVAX
/ Key word(s): Conference
Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United... ► Artikel lesen | |
| HALOZYME THERAPEUTICS | 60,98 | -0,16 % | Halozyme Therapeutics, Inc.: Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s | Royalty revenue contribution expected to begin as early as 2030
Initial partner targets include derisked MoAs that are approved blockbusters today
Highly scalable... ► Artikel lesen | |
| EXACT SCIENCES | 47,555 | -0,85 % | What Analysts Are Saying About Exact Sciences Stock | ||
| BASILEA | 51,40 | -0,39 % | Basilea Pharmaceutica - BARDA backs latest antibacterial programme | Basilea Pharmaceutica has secured a BARDA contract of up to $159m to advance ceftibuten-ledaborbactam etzadroxil, its recently in-licensed oral, Phase III-ready antibiotic for complicated urinary tract... ► Artikel lesen | |
| GINKGO BIOWORKS | 13,400 | -1,47 % | Ginkgo Bioworks Reports Second Quarter 2025 Financial Results | Ginkgo provides an update on its restructuring, including achievement of its expanded $250 million cost savings targets
BOSTON, Aug. 7, 2025 /PRNewswire/ --... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 1,886 | -1,52 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | SAN CARLOS, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering... ► Artikel lesen |
Das Unternehmen CARIS LIFE SCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,600 (+2,36 %) liegt der Kurs bei 26,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CARIS LIFE SCIENCES INC finden Sie auf Wallstreet Online.